Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 249-171-5 | CAS number: 28706-25-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 8.23 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 150
- Dose descriptor starting point:
- NOAEC
- Value:
- 882 mg/m³
- Explanation for the modification of the dose descriptor starting point:
NAEC worker (8h) = (1000 mg/kg bw/0.38 m³/kg bw) * 6.7 m³/ 10 m³ *1.4 * 0.5 [where: NAEC is the
modified starting point; 1000 mg/kg bw is the NOAEL for repeated oral toxicity; 0.38 m³/kg bw is the default respiratory volume for the rat corresponding to the daily duration of 1human exposure; for workers a further correction is needed for the difference between respiratory rates under standard conditions and under conditions of light activity. This correction factor derives from the
inhalation volumes in 8 hours under the respective conditions (6.7 m3 for base level, 10 m3 for light activity)]; 1.4 is Correction for differences between human and experimental exposure conditions; 0,5 is Correction for bioavailability- AF for dose response relationship:
- 1
- Justification:
- Data well supported
- AF for differences in duration of exposure:
- 6
- Justification:
- Subacute to chronic
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Scaling issues just evaluated in modified starting point
- AF for other interspecies differences:
- 2.5
- Justification:
- Remaining differences
- AF for intraspecies differences:
- 5
- Justification:
- Worker population
- AF for the quality of the whole database:
- 2
- Justification:
- read across substance
- AF for remaining uncertainties:
- 1
- Justification:
- Good quality and reliability
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.33 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 600
- Dose descriptor starting point:
- NOAEL
- Value:
- 1 000 mg/kg bw/day
- AF for dose response relationship:
- 1
- Justification:
- Data well supported
- AF for differences in duration of exposure:
- 6
- Justification:
- subacute to chronic
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- allometric rat to human
- AF for other interspecies differences:
- 2.5
- Justification:
- remaining differences
- AF for intraspecies differences:
- 5
- Justification:
- workers
- AF for the quality of the whole database:
- 2
- Justification:
- read across
- AF for remaining uncertainties:
- 1
- Justification:
- Good quality and reliability
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
Kinetics (absorption for oral, dermal and inhalation route of exposure)
No data on absorption are available. According to Chapter R.8 of REACH Guidance on information requirements and chemical safety assessment, it is proposed in the absence of route-specific information on the starting route, to include a default factor of 2 in the case of oral-to-inhalation extrapolation. This approach was taken forward to DNEL derivation. For dermal absorption, based on the physical-chemical properties of the substance (molecular weight > 500 g/mol [1061 g/mol], log Kow < -1 [-4.2 at 23⁰C], water solubility > 10000 mg/L [218 g/L}) low uptake is expected. Low dermal absorption is supported by the absence of adverse effects in the acute dermal toxicity study with Direct Red 239. Based on the above physical-chemical properties, oral absorption is also expected to be low. The absence of systemic effects at the high doses tested in the available oral toxicity studies with Direct Red 239 supports low oral absorption. As both oral and dermal absorption are expected to be low a default factor of 1 for oral-to-dermal extrapolation was used for DNEL derivation.
Acute toxicity
Direct Red 239 does not have to be classified for acute toxicity and therefore derivation of a DNELacuteis not necessary.
Repeated dose toxicity
A subacute oral toxicity study is available for the read across substance Analogue substance 1. In this study male and female rats received the substance by oral gavage at 1000 mg/kg bw/day on 5 days per week over a 30-day period.The treatment period was followed by a 2-wk recovery period.No treatment-related reactions were observed with respect to clinical symptoms, mortality, food consumption, body weight, clinical laboratory investigations and pathology. Furthermore, eye examination did not reveal any ocular changes and no loss of hearing ability was observed. The NOAEL from this study was 1000 mg/kg bw/day. This NOAEL is supported by the absence of adverse effects at 1000 mg/kg bw/day, the highest dose tested, in an oral reproduction/developmental toxicity screening study with Direct Red 239. Hence, a NOAEL of 1000 mg/kg bw/day for systemic effects was used as starting point for the DNEL derivation.
Mutagenicity
Direct Red 329 was not mutagenic in the Ames test. No chromosome aberration or gene mutation test in mammalian cells is available for Direct red 239. However, for a structural analogue of Direct Red 239 (Analogue substance 1) a gene mutation test in mouse lymphoma L5178Y cells is available. This gene mutation test also covers chromosome aberrations because during evaluation small and large colonies were distinguished. Under the conditions of this gene mutation test with the structural analogue, the test substance was non-mutagenic and non-clastogenic.
Reproduction toxicity
No adverse effects on parents or offspring were observed in areproduction/developmental toxicity screening test (OECD 421) in which rats received Direct Red 239by oral gavage at 0, 100, 300 or 1000 mg/kg bw/day. Thus, the NOAEL for reproductive toxicity was 1000 mg/kg bw/day. As this NOAEL is the same as that for repeated dose toxicity (derived from the subacute oral toxicity study with Analogue substance 1), no specific DNEL has to be derived for developmental and reproductive toxicity.
DNEL derivation
Short-term toxicity (systemic and local):
No DNEL needs to be derived for all routes of exposure.
Long-term toxicity:
Inhalation long-term exposure, systemic effects
In the absence of route-specific information, route-to-route extrapolation was performed for DNEL calculation. A default factor of 2 for oral-to-inhalation extrapolation was used as proposed inChapter R.8.4.2 of the REACH Guidance on information requirements and chemical safety assessment. It was assumed that there is no first pass effect (data to demonstrate this are lacking). The NOAEL from the repeated-dose oral toxicity study with the read across substance was used for derivation of the DNELlong-termfor the inhalation route.
Inhalation long-term exposure, local effects
No data are available based on which a DNEL for local effects can be derived. There are also no data to suggest that the substance may cause local effects by inhalation exposure.
Dermal long-term exposure, systemic effects
In the absence of route-specific information, route-to-route extrapolation was performed for DNEL calculation. A default factor of 1 for oral-to-dermal extrapolation was used as proposed inChapter R.8.4.2 of the REACH Guidance on information requirements and chemical safety assessment. It was assumed that there is no first pass effect (data to demonstrate this are lacking). The NOAEL from the repeated-dose oral toxicity study with the read across substance was used for derivation of the DNELlong-termfor the dermal route.
Dermal long-term exposure, local effects
No data are available based on which a DNEL for local effects can be derived. As the substance is not irritating or sensitizing to skin, no local effects are expected for repeated dermal exposure.
Oral long-term exposure, systemic effects
The NOAEL of 1000 mg/kg bw/day for systemic toxicity obtained in the repeated dose oral toxicity study with the read across substance, which was supported by the results of the reproduction / developmental toxicity screening test (OECD TG 421) with Direct red 239, was used for DNEL derivation.
Worker DNELs
Long-term –inhalation, systemic effects(based on repeated dose oral toxicity study with read across substance in rats)
Description | Value | Remark |
Step 1) Relevant dose-descriptor | NOAEL: 1000 mg/kg bw/day | Highest dose tested. No effects observed. |
Step 2) Modification of starting point | 2
0.38 m3/kg bw
6.7 m3/10 m3 | Ratio of inhalation to oral absorption (default value, as proposed in the REACH guidance (R.8.4.2)
Standard respiratory volume of a rat, corrected for 8 h exposure, as proposed in the REACH Guidance (R.8.4.2)
Correction for activity driven differences of respiratory volumes in workers compared to workers in rest (6.7 m3/10 m3). |
Modified dose-descriptor | (1000 / 2 / 0.38) x (6.7/10) = 882 mg/m3 | |
Step 3) Assessment factors |
|
|
Interspecies | 1 | No allometric scaling has to be applied in case of oral to inhalation route to route extrapolation. |
Interspecies variability, remaining differences | 2.5 | remaining differences |
Intraspecies | 5 | Default assessment factor for worker |
Exposure duration | 6 | Extrapolation from subacute to chronic |
Dose response | 1 |
|
Quality of database | 2 | Read across |
DNEL | Value | |
| 882 / (1 x 5 x 2.5 x 6 x 1 x 2) = 882 / 150 = 8.23 mg/m3 |
Long-term – dermal, systemic effects(based on repeated dose oral toxicity study with read across substance in rats)
Description | Value | Remark |
Step 1) Relevant dose-descriptor | NOAEL: 1000 mg/kg bw/day | Highest dose tested. No effects observed. |
Step 2) Modification of starting point | 1 | As both oral and dermal absorption are expected to be low adefault factor of 1 for oral-to-dermal extrapolation was used. |
Step 3) Assessment factors |
|
|
Interspecies | 4 | Assessment factor for allometric scaling |
Interspecies variability, remaining differences | 2.5 | Remaining differences |
Intraspecies | 5 | Default assessment factor for worker |
Exposure duration | 6 | Extrapolation from subacute to chronic |
Dose response | 1 |
|
Quality of database | 2 | Read across |
DNEL | Value | |
| 1000 / (4 x2.5 x 5 x 6 x 1 x 2) *1,4= (1000 / 600)*1,4 = 2.33 mg/kg bw/day |
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.9 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 300
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 435 mg/m³
- Explanation for the modification of the dose descriptor starting point:
NAEC general population (24h) = (1000 mg/kg bw/1.15 m³/kg bw / 2) [where: NAEC is the modified starting point; 1000 mg/kg bw is the NOAEL for repeated oral dose; 1.15 m³/kg bw is the default respiratory volume for the rat corresponding to the daily duration of human exposure; 2 is Ratio of inhalation to oral absorption (default value, as proposed in the REACH guidance (R.8.4.2)
- AF for dose response relationship:
- 1
- Justification:
- Data well supported
- AF for differences in duration of exposure:
- 6
- Justification:
- Subacute to chronic
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Scaling issues just evaluated in modified starting point
- AF for other interspecies differences:
- 2.5
- Justification:
- remaining differences
- AF for intraspecies differences:
- 10
- Justification:
- general population
- AF for the quality of the whole database:
- 2
- Justification:
- read across
- AF for remaining uncertainties:
- 1
- Justification:
- Good quality and reliability
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.83 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 1 200
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 1 000 mg/kg bw/day
- AF for dose response relationship:
- 1
- Justification:
- Data well supported
- AF for differences in duration of exposure:
- 6
- Justification:
- From sub-acute to chronic
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- allometric rat to human
- AF for other interspecies differences:
- 2.5
- Justification:
- remaining differences
- AF for intraspecies differences:
- 10
- Justification:
- General population
- AF for the quality of the whole database:
- 2
- Justification:
- read across
- AF for remaining uncertainties:
- 1
- Justification:
- Good quality and reliability
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.83 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 1 200
- Dose descriptor starting point:
- NOAEL
- Value:
- 1 000 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- AF for dose response relationship:
- 1
- Justification:
- Data well supported
- AF for differences in duration of exposure:
- 6
- Justification:
- From sub-acute to chronic
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- allometric rat to human
- AF for other interspecies differences:
- 2.5
- Justification:
- other differences
- AF for intraspecies differences:
- 10
- Justification:
- General popoulation
- AF for the quality of the whole database:
- 2
- Justification:
- read across
- AF for remaining uncertainties:
- 1
- Justification:
- Good quality and reliability
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
Kinetics (absorption for oral, dermal and inhalation route of exposure)
No data on absorption are available. According to Chapter R.8 of REACH Guidance on information requirements and chemical safety assessment, it is proposed in the absence of route-specific information on the starting route, to include a default factor of 2 in the case of oral-to-inhalation extrapolation. This approach was taken forward to DNEL derivation. For dermal absorption, based on the physical-chemical properties of the substance (molecular weight > 500 g/mol [1061 g/mol], log Kow < -1 [-4.2 at 23⁰C], water solubility > 10000 mg/L [218 g/L}) low uptake is expected. Low dermal absorption is supported by the absence of adverse effects in the acute dermal toxicity study with Direct Red 239. Based on the above physical-chemical properties, oral absorption is also expected to be low. The absence of systemic effects at the high doses tested in the available oral toxicity studies with Direct Red 239 supports low oral absorption. As both oral and dermal absorption are expected to be low a default factor of 1 for oral-to-dermal extrapolation was used for DNEL derivation.
Acute toxicity
Direct Red 239 does not have to be classified for acute toxicity and therefore derivation of a DNELacuteis not necessary.
Repeated dose toxicity
A subacute oral toxicity study is available for the read across substance Analogue substance 1. In this study male and female rats received the substance by oral gavage at 1000 mg/kg bw/day on 5 days per week over a 30-day period.The treatment period was followed by a 2-wk recovery period.No treatment-related reactions were observed with respect to clinical symptoms, mortality, food consumption, body weight, clinical laboratory investigations and pathology. Furthermore, eye examination did not reveal any ocular changes and no loss of hearing ability was observed. The NOAEL from this study was 1000 mg/kg bw/day. This NOAEL is supported by the absence of adverse effects at 1000 mg/kg bw/day, the highest dose tested, in an oral reproduction/developmental toxicity screening study with Direct Red 239. Hence, a NOAEL of 1000 mg/kg bw/day for systemic effects was used as starting point for the DNEL derivation.
Mutagenicity
Direct Red 329 was not mutagenic in the Ames test. No chromosome aberration or gene mutation test in mammalian cells is available for Direct red 239. However, for a structural analogue of Direct Red 239 (Analogue substance 1) a gene mutation test in mouse lymphoma L5178Y cells is available. This gene mutation test also covers chromosome aberrations because during evaluation small and large colonies were distinguished. Under the conditions of this gene mutation test with the structural analogue, the test substance was non-mutagenic and non-clastogenic.
Reproduction toxicity
No adverse effects on parents or offspring were observed in areproduction/developmental toxicity screening test (OECD 421) inwhich rats received Direct Red 239by oral gavage at 0, 100, 300 or 1000 mg/kg bw/day. Thus, the NOAEL for reproductive toxicity was 1000 mg/kg bw/day. As this NOAEL is the same as that for repeated dose toxicity (derived from the subacute oral toxicity study with Analogue substance 1), no specific DNEL has to be derived for developmental and reproductive toxicity.
DNEL derivation
Short-term toxicity (systemic and local):
No DNEL needs to be derived for all routes of exposure.
Long-term toxicity:
Inhalation long-term exposure, systemic effects
In the absence of route-specific information, route-to-route extrapolation was performed for DNEL calculation. A default factor of 2 for oral-to-inhalation extrapolation was used as proposed inChapter R.8.4.2 of the REACH Guidance on information requirements and chemical safety assessment. It was assumed that there is no first pass effect (data to demonstrate this are lacking). The NOAEL from the repeated-dose oral toxicity study with the read across substance was used for derivation of the DNELlong-termfor the inhalation route.
Inhalation long-term exposure, local effects
No data are available based on which a DNEL for local effects can be derived. There are also no data to suggest that the substance may cause local effects by inhalation exposure.
Dermal long-term exposure, systemic effects
In the absence of route-specific information, route-to-route extrapolation was performed for DNEL calculation. A default factor of 1 for oral-to-dermal extrapolation was used as proposed in Chapter R.8.4.2 of the REACH Guidance on information requirements and chemical safety assessment. It was assumed that there is no first pass effect (data to demonstrate this are lacking). The NOAEL from the repeated-dose oral toxicity study with the read across substance was used for derivation of the DNELlong-termfor the dermal route.
Dermal long-term exposure, local effects
No data are available based on which a DNEL for local effects can be derived. As the substance is not irritating or sensitizing to skin, no local effects are expected for repeated dermal exposure.
Oral long-term exposure, systemic effects
The NOAEL of 1000 mg/kg bw/day for systemic toxicity obtained in the repeated dose oral toxicity study with the read across substance, which was supported by the results of the reproduction / developmental toxicity screening test (OECD TG 421) with Direct red 239, was used for DNEL derivation.
General population DNELs
Long-term – oral, systemic effects (based on repeated dose oral toxicity study with read across substance in rats)
Description | Value | Remark |
Step 1) Relevant dose-descriptor | NOAEL: 1000 mg/kg bw/day | Highest dose tested. No effects observed. |
Step 2) Modification of starting point | - | - |
Step 3) Assessment factors |
|
|
Interspecies variability, remaining differences | 2.5 | Remaining differences |
Interspecies | 4 | Assessment factor for allometric scaling. |
Intraspecies | 10 | Default assessment factor for general population |
Exposure duration | 6 | Extrapolation from subacute to chronic |
Dose response | 1 |
|
Quality of database | 2 | Read across |
DNEL | Value | |
| 1000 / (2.5 x 4 x 10 x 6 x 1 x 2) =1000 / 1200 = 0.83 mg/kg bw/day |
Long-term – inhalation, systemic effects (based on repeated dose oral toxicity study with read across substance in rats)
Description | Value | Remark |
Step 1) Relevant dose-descriptor | NOAEL: 1000 mg/kg bw/day | Highest dose tested. No effects observed. |
Step 2) Modification of starting point | 2
1.15 m3/kg bw
| Ratio of inhalation to oral absorption (default value, as proposed in the REACH guidance (R.8.4.2)
Standard respiratory volume of a rat, corrected for 24 h exposure, as proposed in the REACH Guidance (R.8.4.2) |
Modified dose-descriptor | (1000 / 2) x (1/1.15) = 435 mg/m3 | |
Step 3) Assessment factors |
|
|
Interspecies | 1 | No allometric scaling has to be applied in case of oral to inhalation route to route extrapolation. |
Interspecies variability, remaining differences | 2.5 | remaining differences |
Intraspecies | 10 | Default assessment factor for general population |
Exposure duration | 6 | Extrapolation from subacute to chronic |
Dose response | 1 |
|
Quality of database | 2 | Read across |
DNEL | Value | |
| 435 / (1 x 2.5 x 10 x 6 x 1 x 2) = 435 / 300 = 1.45 mg/m3 |
Long-term – dermal, systemic effects (based on repeated dose oral toxicity study with read across substance in rats)
Description | Value | Remark |
Step 1) Relevant dose-descriptor | NOAEL: 1000 mg/kg bw/day | Highest dose tested. No effects observed. |
Step 2) Modification of starting point | 1 | As both oral and dermal absorption are expected to be low adefault factor of 1 for oral-to-dermal extrapolation was used |
Step 3) Assessment factors |
|
|
Interspecies | 4 | Assessment factor for allometric scaling. |
Intraspecies | 10 | Default assessment factor for general population |
Interspecies variability, remaining differences | 2.5 | remaining differences |
Exposure duration | 6
| Extrapolation from subacute to chronic |
Dose response | 1 |
|
Quality of database | 2 | Read across |
DNEL | Value | |
| 1000 / (4 x 10 x 2.5 x 6 x 1 x 2) =1000 / 1200 = 0.83 mg/kg bw/day |
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.